

4000
3000
2000
1000
0
1/v (umole/min/ml)-1
5
-4
-3
-2
-1
0
1
2
3
4
5
Inhibitor µM

Fig.1A(i)



3000
2500
2000
1500
1000
500
0
1/v (umole/min/ml)-1
-9
-8
-7
-6
-5
-4
-3
-2
-1
0
1
2
3
4
5
µM Inhibitor

Fig.1A(ii)



12000
10000
8000
6000
4000
2000
0
1/v (umole/min/ml)-1
4
-2
0
2
4
6
8
µM Inhibitor

Fig.1B(i)




Fig.1B(ii)



7000
6000
5000
4000
3000
2000
1000
0
1/v (µmole/min/ml)-1
4
-2
0
2
4
6
8
µM Inhibitor

Fig.1C(i)



8000
7000
6000
5000
4000
3000
2000
1000
0
1/v (umole/min/ml)-1
-2
0
2
4
6
8
10
µM Inhibitor

Fig.1C(ii)



4000
3000
2000
1000
0
1/v (µmole/min.ml)-1
20
-15
-10
-5
0
5
10
15
µM Inhibitor

Fig.1D(i)



4000
3000
2000
1000
0
1/v (umole/min/ml)-1
20
-10
0
10
20
µM Inhibitor

Fig.1D(ii)




Fig. 2 (A) NAV-048 docked with *P. falciparum* Enoyl-ACP reductase.




Fig. 2 (B). NAV-029 docked with *P. falciparum* Enoyl-ACP reductase.




Fig. 2 (C). NAV-082 docked with *P. falciparum* Enoyl-ACP reductase.




Fig. 2 (D). NAV-083 docked with *P. falciparum* Enoyl-ACP reductase.




Fig. 2 (E). NAV-038 docked with *P. falciparum* Enoyl-ACP reductase.





Figure 3



[Compound NAV-117]nM

Figure 4



3.0
2.5
2.0
1.5
1.0
0.5
0.0
-300
-200
-100
0
100
200
300
1/V (pmol/ml/min)-1
Compound NAV-117 (nM)

Figure 5



100
80
60
40
20
0
Relative percent parasitemia
-1.0
-0.5
0.0
0.5
1.0
log (μM of inhibitor)

Figure 6



4000
3000
2000
1000
0
1/v (umole/min/ml)-1
5
-4
-3
-2
-1
0
1
2
3
4
5
Inhibitor μM

Fig.1A(i)



1/v (umole/min/ml)-1
3000
2500
2000
1500
1000
500
0
-8
-7
-6
-5
-4
-3
-2
-1
0
1
2
3
4
5
µM inhibitor

Fig.1A(ii)



12000
10000
8000
6000
4000
2000
0
1/v (umole/min/ml)-1
4
-2
0
2
4
6
8
µM Inhibitor

Fig.1B(i)



20000
15000
10000
5000
0
1/v (umole/min/ml)-1
-2
0
2
4
6
8
µM Inhibitor

Fig.1B(ii)



7000
6000
5000
4000
3000
2000
1000
0
1/v (umole/min/ml)-1
4
-2
0
2
4
6
8
µM Inhibitor

Fig.1C(i)



8000
7000
6000
5000
4000
3000
2000
1000
0
1/v (umole/min/ml)-1
-2
0
2
4
6
8
10
µM Inhibitor

Fig.1C(ii)



4000
3000
2000
1000
0
1/v (umole/min.ml)-1
20
-15
-10
-5
0
5
10
15
µM Inhibitor

Fig.1D(i)



4000
3000
2000
1000
0
1/v (umole/min/ml)-1
20
-10
0
10
20
µM Inhibitor

Fig.1D(ii)




Fig. 2 (A) NAV-048 docked with *P. falciparum* Enoyl-ACP reductase.




Fig. 2 (B). NAV-029 docked with *P. falciparum* Enoyl-ACP reductase.




Fig. 2 (C). NAV-082 docked with *P. falciparum* Enoyl-ACP reductase.




Fig. 2 (D). NAV-083 docked with *P. falciparum* Enoyl-ACP reductase.






Fig. 2 (E). NAV-038 docked with *P. falciparum* Enoyl-ACP reductase.




log [NAV-117]nM

Figure 3



[Compound NAV-117]nM

Figure 4



Compound NAV-117 (nM)

Figure 5



100
80
60
40
20
0
Relative percent parasitemia
-1.0
-0.5
0.0
0.5
1.0
log (µM of inhibitor)

Figure 6